Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Faeth Therapeutics, a clinical-stage oncology company, has announced its participation in two upcoming investor conferences. The events include the Wells Fargo 21st Annual Healthcare Conference and the Citi Biopharma Back to School Summit. This engagement aims to showcase their lead program, PIKTOR, and connect with potential investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth Therapeutics is actively engaging with investors.
  • Participation in notable conferences may enhance visibility.
  • The company is focused on developing innovative cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~35 mo
Minimal dilution risk
Lead asset
PAN-301-1
Phase 1 · Prostate Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MACiti Biopharma Back to School SummitWednesday, September 9, 2026Fireside chat at 10:00 a.m. ETNew York, NYCantor G

Frequently Asked Questions

What is Faeth Therapeutics known for?

Faeth Therapeutics is a clinical-stage oncology company developing multi-node therapies for cancer.

When will Faeth participate in investor conferences?

Faeth will participate in conferences on September 8 and 9, 2026.

What is the lead program of Faeth Therapeutics?

The lead program of Faeth Therapeutics is called PIKTOR.

Where will the investor conferences take place?

The conferences will be held in Boston, MA, and New York, NY.

ShareAdd on Google
Tags: FTH Viatris Investor Conferences Healthcare Faeth Therapeutics PIKTOR investor conferences oncology
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$186M liquidity · $5M/mo burn
~35 mo
Minimal dilution risk
Lead asset
PAN-301-1Phase 1
Prostate Cancer →